EDN1 and pulmonary arterial hypertension: One implication of this study is that use of ET-1 receptor antagonists (ERAs)—which have regulatory approval for treatment of PAH in several countries, might adversely affect right ventricular function (Nagendran et al. 2013)—hence, studies such as the present one, which provide improved insight into hypertrophic cellular processes, will enhance both safety and efficacy of various therapies for potentially pathological effects of ET-1.